Journal
AMERICAN JOURNAL OF CLINICAL NUTRITION
Volume 93, Issue 3, Pages 564-568Publisher
AMER SOC CLINICAL NUTRITION
DOI: 10.3945/ajcn.110.005413
Keywords
-
Categories
Funding
- Cystic Fibrosis Foundation
- Michael Smith Foundation for Health Research
Ask authors/readers for more resources
Background: Choline is an important constituent of acetylcholine. Choline is needed for acetylcholine in the nonneuronal acetylcholine system that includes epithelial cells of the lung and intestine, endothelial cells, and immune cells. Plasma free choline concentrations are low in children with cystic fibrosis (CF), but the implications for acetylcholine are unknown. Objective: We determined the relation between plasma free choline and related metabolites and leukocyte acetylcholine in children with CF and in a control group of healthy children without CF. Design: This was a cross-sectional study in 34 children with CF who were pancreatic insufficient and taking pancreatic enzyme-replacement therapy and in 16 healthy children. Plasma free choline, betaine, dimethylglycine, methionine, homocysteine, and leukocyte acetylcholine concentrations were quantified by using isotope-dilution HPLC-tandem mass spectrometry. Results: Mean (+/- SE) plasma free choline was 9.30 +/- 0.37 and 6.54 +/- 0.38 mu mol/L (P < 0.05) and leukocyte acetylcholine was 1.21 +/- 0.016 and 0.077 +/- 0.011 pmol leukocyte acetylcholine/10(6) cells (P < 0.05) in control children and children with CF, respectively. Leukocyte acetylcholine was positively correlated with plasma free choline concentration in children with CF (r = 0.412, P < 0.05) but not in control children. Plasma betaine, dimethylglycine, and methionine concentrations were also lower in children with CF than in control children (P < 0.05). Conclusions: A low free choline and methyl status in children with CF is associated with reduced acetylcholine in leukocytes. Whether these changes are explained by a mutation in the CF transmembrane conductance regulator or disturbances in choline metabolism and the implications for immune cell dysfunction in CF are unknown. This trial was registered at clinicaltrials.gov as NCT01150136. Am J Clin Nutr 2011;93:564-8.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available